share_log

Editas Medicine shares are trading lower after Morgan Stanley maintained an Underweight rating on the stock and lowered its price target from $17 to $15.

Benzinga ·  May 9, 2022 10:56
Editas Medicine shares are trading lower after Morgan Stanley maintained an Underweight rating on the stock and lowered its price target from $17 to $15.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment